UBS Lifts Exponent Price Target After Optimistic Management Meetings

Core Viewpoint - UBS has raised its price target on Exponent (NASDAQ:EXPO) to $81 from $76 while maintaining a Neutral rating, following recent investor meetings with company management [1] Group 1: Management Outlook - Management conveyed a more optimistic outlook, suggesting a return to full-time equivalent employee growth could position Exponent for an improved revenue trajectory in 2026 [2] - UBS noted signs of a strengthening demand environment, particularly in proactive industries like consumer electronics, which are beginning to recover after a period of softness [2] Group 2: Financial Momentum - UBS indicated that the company's financial momentum appears to be accelerating into 2026 [3] - UBS argued that Exponent is better positioned compared to broader consulting and AI-related concerns due to its premium offerings and highly technical expertise [3] - Based on these factors, UBS stated that the setup for Exponent shares appears to be improving [3]